Stockreport

ContraVir Pharmaceuticals Announces Data on Optimized Formulation of TXL™

CONTRAVIR PHARMACEUTICALS INC  (CTRV) 
US:NASDAQ Investor Relations: ir.contravir.com/investor-relations
PDF EDISON, N.J., June 21, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercializa [Read more]